Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: Interspecies differences

British Journal of Pharmacology

Volumn 152, Issue 5, 2007, Pages 583-593

  McPartland, J M ^a   Glass, M ^b   Pertwee, R G ^c  

^a Porton Down Science Park   (United Kingdom)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Anandamide; Cannabinoid; Cannabis; Directed molecular evolution; Endocannabinoid; Meta analysis; Pharmacogenetics; Species specificity; Structure activity relationship; Tetrahydrocannabinol

Indexed keywords

2 ARACHIDONOYL GLYCEROL; ANANDAMIDE; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOL; CP55,940; FLUORIDE; GLYCEROL DERIVATIVE; LIGAND; PHENYLMETHYLSULPHONYL FLUORIDE; RADIOLIGAND; RIMONABANT; TETRAHYDROCANNABINOL DERIVATIVE; UNCLASSIFIED DRUG; WIN55,212 2;

AUTORADIOGRAPHY; BINDING AFFINITY; BRAIN; BRAIN CORTEX; BRAIN REGION; BRAIN TISSUE; CENTRIFUGATION; CEREBELLUM; COCHRANE LIBRARY; COMPARATIVE STUDY; DRUG DISTRIBUTION; FILTRATION; GENETIC TRANSFECTION; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIGAND BINDING; LITERATURE; META ANALYSIS; METHODOLOGY; MOVEMENT (PHYSIOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; QUANTITATIVE STUDY; REVIEW; SENSITIVITY ANALYSIS; SPECIES DIFFERENCE; VALIDITY;

ANIMALS; BINDING, COMPETITIVE; CANNABINOIDS; HUMANS; LIGANDS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SPECIES SPECIFICITY;

EID: 35648934575     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707399     Document Type: Review

References (59)

1. Andersson H, D'Antona AM, Kendall DA, Von Heijne G, Chin CN (2003). Membrane assembly of the cannabinoid receptor 1: impact of a long N-terminal tail. Mol Pharmacol 64: 570-577.
2. Arnold JC, Topple AN, Mallet PE, Hunt GE, McGregor IS (2001). The distribution of cannabinoid-induced Fos expression in rat brain: differences between the Lewis and Wistar strain. Brain Res 921: 240-255.
3. Astolfi M, Patacchini R, Maggi M, Manzini S (1997). Improved discriminatory properties between human and murine tachykinin NK1 receptors of MEN 10930: a new potent and competitive antagonist. Neuropeptides 31: 373-379.
4. Baker D, Pryce G, Davies WL, Hiley CR (2006). In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 27: 1-4.
5. Bingham B, Jones PG, Uveges AJ, Kotnis S, Lu P, Smith VA et al. (2007). Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers. Br J Pharmacol: 2007 Jun 4 [E-pub ahead of print].
6. Boyce MS, Irwin LL, Barker R (2005). Demographic meta-analysis: synthesizing vital rates for spotted owls. J Appl Ecol 42: 38-49.
7. Breivogel CS, Griffin G, Di Marzo V, Martin BR (2001). Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60: 155-163.
8. Breivogel CS, Sim LJ, Childers SR (1997). Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J Pharmacol Exp Ther 282: 1632-1642.
9. Browne RG, Weissman A (1981). Discriminative stimulus properties of delta 9-tetrahydrocannabinol: mechanistic studies. J Clin Pharmacol 21: 227S-234S.
10. Cochran W (1954). The combination of estimates from different experiments. Biometrics 10: 101-124.
11. Demuth DG, Molleman A (2006). Cannabinoid signalling. Life Sci 78: 549-563.
12. Diaz-Laviada I, Ruiz-Llorente L (2005). Signal transduction activated by cannabinoid receptors. Mini Rev Med Chem 5: 619-630.
13. Egertova M, Elphick MR (2000). Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. J Comp Neurol 422: 159-171.
14. Eggan SM, Lewis DA (2006). Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cereb Cortex 17: 175-191.
15. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O et al. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48: 443-450.
16. Felder CC, Veluz JS, Williams HL, Briley EM, Matsuda LA (1992). Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol Pharmacol 42: 838-845.
17. Glass GV, McGaw B, Smith ML (1981). Meta-analysis in Social Research. SAGE Publications: Beverly Hills, CA.
18. Glass M(1995). Doctorate Dissertation, Department of Pharmacology and Clinical Pharmacology. University of Auckland: Auckland, pp. 220.
19. Glass M, Dragunow M, Faull RL (1997). Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77: 299-318.
20. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A et al. (2006). Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 1071: 10-23.
21. Guy G, Robson R, Strong K, Whittle B (2004). The Medicinal Use of Cannabis. Royal Society of Pharmacists: London.
22. Haller J, Matyas F, Soproni K, Varga B, Barsy B, Nemeth B et al. (2007). Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission. Eur J Neurosci 25: 2445-2456.
23. Harkany T, Dobszay MB, Cayetanot F, Hartig W, Siegemund T, Aujard F et al. (2005). Redistribution of CB1 cannabinoid receptors during evolution of cholinergic basal forebrain territories and their cortical projection areas: a comparison between the gray mouse lemur (Microcebus murinus, primates) and rat. Neuroscience 135: 595-609.
24. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR et al. (1990). Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87: 1932-1936.
25. Higgins JPT, Green S (2005). Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. [updated May 2005]. In: Higgins JPT, Green S (eds) The Cochrane Library. John Wiley & Sons, Ltd.: Chichester, UK.
26. Hoffman AF, Macgill AM, Smith D, Oz M, Lupica CR (2005). Species and strain differences in the expression of a novel glutamate-modulating cannabinoid receptor in the rodent hippocampus. Eur J Neurosci 22: 2387-2391.
27. Houston DB, Howlett AC (1998). Differential receptor-G-protein coupling evoked by dissimilar cannabinoid receptor agonists. Cell Signal 10: 667-674.
28. Howlett AC (2002). The cannabinoid receptors. Prostaglandins Other Lipid Mediat 68-69: 619-631.
29. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F et al. (2002). An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 99: 8400-8405.
30. Hungund BL, Basavarajappa BS (2000). Distinct differences in the cannabinoid receptor binding in the brain of C57BL/6 and DBA/2 mice, selected for their differences in voluntary ethanol consumption. J Neurosci Res 60: 122-128.
31. Isbell H, Gorodetzsky CW, Jasinski D, Claussen U, Von Spulak F, Korte F (1967). Effects of (-)delta-9-trans-tetrahydrocannabinol in man. Psychopharmacologia 11: 184-188.
32. Jarbe TU, Johansson JO, Henriksson BG (1976). Characteristics of tetrahydrocannabinol (THC)-produced discrimination in rats. Psychopharmacology (Berlin) 48: 181-187.
33. Kearn CS, Greenberg MJ, DiCamelli R, Kurzawa K, Hillard CJ (1999). Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. J Neurochem 72: 2379-2387.
34. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F (1997). Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 337: 536-542.
35. Martini L, Waldhoer M, Pusch M, Kharazia V, Fong J, Lee JH et al. (2007). Ligand-induced down-regulation of the cannabinoid 1 receptor is mediated by the G-protein-coupled receptor-associated sorting protein GASP1. FASEB J 21: 802-811.
36. Mauler F, Mittendorf J, Horvath E, De Vry J (2002). Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4, 4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J Pharmacol Exp Ther 302: 359-368.
37. McPartland JM, Matias I, Di Marzo V, Glass M (2006). Evolutionary origins of the endocannabinoid system. Gene 370: 64-74.
38. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK (1980). Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28: 409-416.
39. Overington JP, Al-Lazikani B, Hopkins AL (2006). How many drug targets are there? Nat Rev Drug Discov 5: 993-996.
40. Paugh SW, Cassidy MP, He H, Milstien S, Sim-Selley LJ, Spiegel S et al. (2006). Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor. Mol Pharmacol 70: 41-50.
41. Pertwee RG (2005). Pharmacological actions of cannabinoids. Handb Exp Pharmacol 168: 1-51.
42. Pertwee RG, Thomas A, Stevenson LA, Maor Y, Mechoulam R (2005). Evidence that (-)-7-hydroxy-4′-dimethylheptyl-cannabidiol activates a non-CB(1), non-CB(2), non-TRPV1 target in the mouse vas deferens. Neuropharmacology 48: 1139-1146.
43. Petitet F, Donlan M, Michel A (2006). GPR55 as a new cannabinoid receptor: still a long way to prove it. Chem Biol Drug Des 67: 252-253.
44. 3H]SR141716A. Neuroreport 7: 789-792.
45. Reed GF, Lynn F, Meade BD (2002). Use of coefficient of variation in assessing variability of quantitative assays. Clin Diagn Lab Immunol 9: 1235-1239.
46. Rhee MH, Vogel Z, Barg J, Bayewitch M, Levy R, Hanus L et al. (1997). Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem 40: 3228-3233.
47. Rodriguez de Fonseca F, Gorriti MA, Fernandez-Ruiz JJ, Palomo T, Ramos JA (1994). Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment. Pharmacol Biochem Behav 47: 33-40.
48. Romero J, Fernandez-Ruiz JJ, Vela G, Ruiz-Gayo M, Fuentes JA, Ramos JA (1998). Autoradiographic analysis of cannabinoid receptor binding and cannabinoid agonist-stimulated [35S]GTP gamma S binding in morphine-dependent mice. Drug Alcohol Depend 50: 241-249.
49. Russo EB, Burnett A, Hall B, Parker KK (2005). Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30: 1037-1043.
50. Savinainen JR, Saario SM, Niemi R, Jarvinen T, Laitinen JT (2003). An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors. Br J Pharmacol 140: 1451-1459.
51. Schioth HB, Haitina T, Ling MK, Ringholm A, Fredriksson R, Cerda-Reverter JM et al. (2005). Evolutionary conservation of the structural, pharmacological, and genomic characteristics of the melanocortin receptor subtypes. Peptides 26: 1886-1900.
52. Sese J, Morishita S (2001). Rank aggregation method for biological databases. Genome Inform 12: 506-507.
53. Sheskin T, Hanus L, Slager J, Vogel Z, Mechoulam R (1997). Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem 40: 659-667.
54. Steffens M, Engler C, Zentner J, Feuerstein TJ (2004). Cannabinoid CB1 receptor-mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortex. Br J Pharmacol 141: 1193-1203.
55. Szallasi A (1994). The vanilloid (capsaicin) receptor: receptor types and species differences. Gen Pharmacol 25: 223-243.
56. Thomas BF, Francisco ME, Seltzman HH, Thomas JB, Fix SE, Schulz AK et al. (2005). Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4- methyl-1H-pyra zole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities. Bioorg Med Chem 13: 5463-5474.
57. Thomas BF, Gilliam AF, Burch DF, Roche MJ, Seltzman HH (1998). Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 285: 285-292.
58. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K et al. (2005). Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310: 329-332.
59. Wiley JL, Lowe JA, Balster RL, Martin BR (1995). Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys. J Pharmacol Exp Ther 275: 1-6.